CARM
Price
$1.37
Change
-$0.03 (-2.14%)
Updated
May 16, 6:59 PM EST
FOLD
Price
$9.50
Change
-$0.16 (-1.66%)
Updated
May 16, 6:59 PM EST
76 days until earnings call
Ad is loading...

CARM vs FOLD

Header iconCARM vs FOLD Comparison
Open Charts CARM vs FOLDBanner chart's image
Carisma Therapeutics
Price$1.37
Change-$0.03 (-2.14%)
Volume$96.02K
CapitalizationN/A
Amicus Therapeutics
Price$9.50
Change-$0.16 (-1.66%)
Volume$1.35M
CapitalizationN/A
View a ticker or compare two or three
CARM vs FOLD Comparison Chart

Loading...

CARMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
FOLDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CARM vs. FOLD commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARM is a Hold and FOLD is a Sell.

COMPARISON
Comparison
May 17, 2024
Stock price -- (CARM: $1.37 vs. FOLD: $9.50)
Brand notoriety: CARM and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARM: 106% vs. FOLD: 82%
Market capitalization -- CARM: $58.16M vs. FOLD: $2.81B
CARM [@Biotechnology] is valued at $58.16M. FOLD’s [@Biotechnology] market capitalization is $2.81B. The market cap for tickers in the [@Biotechnology] industry ranges from $592.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARM’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • CARM’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, CARM is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARM’s TA Score shows that 3 TA indicator(s) are bullish while FOLD’s TA Score has 4 bullish TA indicator(s).

  • CARM’s TA Score: 3 bullish, 3 bearish.
  • FOLD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CARM is a better buy in the short-term than FOLD.

Price Growth

CARM (@Biotechnology) experienced а -9.27% price change this week, while FOLD (@Biotechnology) price change was +0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.45%. For the same industry, the average monthly price growth was +4.26%, and the average quarterly price growth was +63.16%.

Reported Earning Dates

CARM is expected to report earnings on May 15, 2023.

FOLD is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Biotechnology (+2.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CARM with price predictions.
OPEN
A.I.dvisor published
a Summary for FOLD with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
FOLD($2.81B) has a higher market cap than CARM($58.2M). FOLD YTD gains are higher at: -33.051 vs. CARM (-53.242).
CARMFOLDCARM / FOLD
Capitalization58.2M2.81B2%
EBITDAN/AN/A-
Gain YTD-53.242-33.051161%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CARM vs FOLD: Fundamental Ratings
CARM
FOLD
OUTLOOK RATING
1..100
5256
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9277
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CARM's Valuation (52) in the null industry is in the same range as FOLD (79) in the Biotechnology industry. This means that CARM’s stock grew similarly to FOLD’s over the last 12 months.

CARM's Profit vs Risk Rating (100) in the null industry is in the same range as FOLD (100) in the Biotechnology industry. This means that CARM’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (98) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that FOLD’s stock grew similarly to CARM’s over the last 12 months.

FOLD's Price Growth Rating (77) in the Biotechnology industry is in the same range as CARM (92) in the null industry. This means that FOLD’s stock grew similarly to CARM’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CARM (100) in the null industry. This means that FOLD’s stock grew similarly to CARM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CARMFOLD
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 5 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
CARMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
FOLDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIGFX26.44N/A
N/A
Baron International Growth Retail
CIMEX24.30-0.02
-0.08%
American Funds Income Fund of Amer 529E
FQITX13.05-0.02
-0.15%
Fidelity SAI International Qly Idx
AAWEX14.03-0.04
-0.28%
Cavanal Hill World Energy A
OGINX45.56-0.23
-0.50%
Invesco Global Opportunities R

CARM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARM has been loosely correlated with PRME. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CARM jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARM
1D Price
Change %
CARM100%
-2.14%
PRME - CARM
43%
Loosely correlated
+4.14%
NTLA - CARM
41%
Loosely correlated
-0.19%
MLYS - CARM
38%
Loosely correlated
+0.61%
FULC - CARM
36%
Loosely correlated
-5.52%
FOLD - CARM
36%
Loosely correlated
-1.66%
More